Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B

Published:2019-11-21 Issue:8 Volume:92 Page:1206-1213
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Shen Sheng¹,Wong Grace L.‐H.²³⁴,Kuang Zhe¹,Campenhout Margo J. H.⁵,Fan Rong¹,Wong Vincent W.‐S.²³⁴,Yip Terry C.‐F.²³,Chi Heng⁵,Liang Xieer¹,Hu Xiaoyun¹,Lin Weiyin¹,Wu Yaobo¹,Liu Xiaoju¹,Boonstra André⁵,Hou Jinlin¹,Sun Jian⁶^ORCID,Chan Henry L.‐Y.²³⁴

Affiliation:

1. State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Disease, Nanfang HospitalSouthern Medical UniversityGuangzhou China

2. Institute of Digestive DiseaseThe Chinese University of Hong KongShatin Hong Kong SAR China

3. Department of Medicine and TherapeuticsThe Chinese University of Hong KongShatin Hong Kong SAR China

4. State Key Laboratory of Digestive DiseaseThe Chinese University of Hong KongShatin Hong Kong SAR China

5. Department of Gastroenterology and HepatologyErasmus MC University Medical CenterRotterdam The Netherlands

6. Department of Infectious DiseasesNanfang Hospital, Southern Medical UniversityGuangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25628

Reference33 articles.

1. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study

2. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B

3. Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection

4. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

5. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis;Viruses;2024-07-12

2. Serum hepatitis B virus spliced RNA proportion increases with liver disease progression in patients with chronic hepatitis B;Journal of Medical Virology;2024-01-31

3. A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues;Annals of Hepatology;2024-01

4. Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections;Viruses;2023-05-03

5. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment;BioMed Research International;2022-07-15